Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Mechanisms of Innate and Acquired Resistance to Anti-EGFR therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies.

Parseghian CM, Napolitano S, Loree JM, Kopetz S.

Clin Cancer Res. 2019 Jul 1. doi: 10.1158/1078-0432.CCR-19-0823. [Epub ahead of print] Review.

PMID:
31263029
2.

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge.

Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S.

Ann Oncol. 2019 Feb 1;30(2):243-249. doi: 10.1093/annonc/mdy509.

PMID:
30462160
3.

Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology.

Parseghian CM, Tam AL, Yao J, Ensor J Jr, Ellis LM, Raghav K, Overman MJ.

JAMA Oncol. 2019 Mar 1;5(3):402-405. doi: 10.1001/jamaoncol.2018.4640.

PMID:
30383128
4.

Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy.

Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S.

J Immunother. 2018 Jul/Aug;41(6):284-291. doi: 10.1097/CJI.0000000000000222.

5.

Underreporting of Research Biopsies from Clinical Trials in Oncology.

Parseghian CM, Raghav K, Wolff RA, Ensor J Jr, Yao J, Ellis LM, Tam AL, Overman MJ.

Clin Cancer Res. 2017 Nov 1;23(21):6450-6457. doi: 10.1158/1078-0432.CCR-17-1449. Epub 2017 Jul 28.

6.

Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.

Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S.

Clin Cancer Res. 2017 Aug 1;23(15):4146-4154. doi: 10.1158/1078-0432.CCR-16-3138. Epub 2017 Mar 9.

7.

Properties of variant forms of human stem cell factor recombinantly expressed in Escherichia coli.

Langley KE, Mendiaz EA, Liu N, Narhi LO, Zeni L, Parseghian CM, Clogston CL, Leslie I, Pope JA, Lu HS, et al.

Arch Biochem Biophys. 1994 May 15;311(1):55-61.

PMID:
7514387

Supplemental Content

Loading ...
Support Center